Lymphoma News

For many in oncology, attending medical conferences is essential to stay up to speed on the latest treatment advances and research. But for one early-career oncologist, attending one meeting was also career changing.

Daily electronic patient-reported outcome assessments may provide valuable insight into symptom management among patients with cancer undergoing antineoplastic treatment, according to a study published in JAMA Network Open.

Adding romidepsin to busulfan and fludarabine reduced incidence of relapse among patients receiving allogeneic stem cell transplant for aggressive T-cell malignancies, according to results of a phase 1/phase 2 study.

As new therapeutic options for mantle cell lymphoma emerge, physicians are learning where they best fit into the treatment armamentarium.

Researchers have developed a novel quantitative assay that can predict which patients will achieve durable remissions after CD19-directed chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma.

Amit Maity, MD, PhD, has been appointed chair of the department of radiation oncology for Spencer Fox Eccles School of Medicine at University of Utah.

ASH announced the 36 recipients of the society’s 2022 Scholar Awards.

The FDA granted priority review to lisocabtagene maraleucel as second-line treatment of adults with relapsed or refractory large B-cell lymphoma.

The FDA placed a clinical hold on a phase 1 trial of LB1901, a chimeric antigen receptor T-cell therapy for treatment of adults with relapsed or refractory T-cell lymphoma.

Second-line therapy with axicabtagene ciloleucel conferred a greater than eightfold increase in median EFS compared with standard-of-care treatment for older patients with diffuse large B-cell lymphoma, according to phase 3 study results.